INTRODUCTION AND OBJECTIVES: Prior experimental studies have shown that the enzyme g-glutamyltransferase (g-GT) is overexpressed during carcinogenetic transformation of urothelial cells. This analysis aimed to elucidate the prognostic value of serum g-GT, glutamat-pyruvat-transaminase (GPT) and glutamat-oxalattransaminase (GOT) levels in patients with invasive bladder cancer (BC).
METHODS: Preoperative serum g-GT, GPT and GOT concentrations were assessed in 324 patients treated with RC for clinically non-metastatic BC between 2002 and 2013. Laboratory values were obtained 1-3 days prior to RC. Uni-and multivariable analyses were carried out to evaluate clinicopathologic features and survival after RC. The median follow-up was 36 months (IQR: 10-55).
RESULTS: Elevated preoperative g-GT, GPT and GOT levels were diagnosed in 77 (23.8%), 20 (6.2%) and 18 (5.5%) patients, respectively. Elevated g-GT levels were significantly associated with advanced tumor stage (pT3a; p¼0.001), lymph-node tumor involvement (p<0.001), positive surgical margins (p¼0.018), lymphovascular invasion (p¼0.024), muscle-invasive disease at primary diagnosis (p¼0.033), increased tumor size (continuously coded; p¼0.035), receipt of neoadjuvant chemotherapy (p¼0.006), higher Eastern Cooperative Performance Status (p¼0.001), hydronephrosis at RC (p¼0.049), increased preoperative serum C-reactive protein levels (p<0.001) and elevated serum GPT and GOT levels (both p<0.001). Patients with elevated g-GT concentration exhibited inferior 3-year disease-free (52.5% vs. 63.2%; p¼0.19), cancer-specific (71.1% vs. 80.9%; p¼0.042) and overall survival rates (49.2% vs. 69.6%; p¼0.005) compared to patients with normal levels. On multivariable analysis, higher ECOG performance status, hydronephrosis at RC (both p¼0.010), positive surgical margin status (p¼0.014), lymph node positive disease (p¼0.030), advanced tumor stage (p¼0.032), and an elevated g-GT concentration (p¼0.043) were independent predictors of all-cause mortality.
CONCLUSIONS: Elevated preoperative g-GT levels are associated with a significantly increased risk for locally advanced bladder cancer and mortality. These data suggest that g-GT levels may be a useful prognostic marker for patients after RC for BC.
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MP88-02 EXPRESSION OF CLASS III BETA-TUBULIN PREDICTS PROGNOSIS IN CISPLATIN-RESISTANT BLADDER CANCER PATIENTS RECEIVING PACLITAXEL-BASED SECOND-LINE CHEMOTHERAPY
Tomohiro Matsuo*, Yasuyoshi Miyata, Yuichiro Nakamura, Takuji Yasuda, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Class III beta-tubulin (TUBB3) is associated with malignant aggressiveness and prognosis, in addition, its expression is recognized as a predictive marker for taxanebased chemotherapy (CTx) in several cancers. In urothelial cancer (UC), standard first-line therapy for advanced disease is cisplatin (CDDP)-based CTx. On the other hand, although second-line regimen for CDDP-resistant tumor is not still established, several studies showed paclitaxel (PTX)-based regimens were effective to improve the prognosis. The main aim is to clarify the predictive value of TUBB3 expression for anti-cancer effect by first-line CDDP-based CTx and second-line PTX-based one in patients with UC.
METHODS: We reviewed 116 UC (bladder cancer ¼ 90 and upper urinary tract cancer ¼ 26) patients treated with CDDP-based regimen as first-line CTx. Among these patients, 53 patients were received PTX-based second-line CTx. As PTX-based CTx, the combination of gemcitabine and PTX were performed in 42 patients. TUBB3 expression was evaluated by immunohistochemical technique, and survival analyses were performed by using Kaplan-Meier survival curves and multivariate COX proportional hazard analysis.
RESULTS: Positively stained ratio of TUBB3 in grade 3 tumors (50 / 74 ¼ 67.6%) was significantly higher (P < 0.001) than that in grade 1 (0 / 5 ¼ 0.0%) and grade 2 (14 / 37 ¼ 37.8%). A similar trend was found in T stage; however, it did not reach the significant level (P ¼ 0.062). No significant relationship was found in age, sex, and metastasis. When the predictive value of TUBB3 expression for CDDP-based first-line CTx was investigated, it is not recognized as a significant predictive factor for progression-free survival (P ¼ 0.796). On the other hand, high expression of TUBB3 is significantly e1174 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
